Annual CFF
$331.01 M
+$46.43 M+16.32%
December 31, 2023
Summary
- As of February 7, 2025, AXSM annual cash flow from financing activities is $331.01 million, with the most recent change of +$46.43 million (+16.32%) on December 31, 2023.
- During the last 3 years, AXSM annual CFF has risen by +$288.60 million (+680.46%).
- AXSM annual CFF is now at all-time high.
Performance
AXSM Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$30.41 M
+$16.03 M+111.47%
September 30, 2024
Summary
- As of February 7, 2025, AXSM quarterly cash flow from financing activities is $30.41 million, with the most recent change of +$16.03 million (+111.47%) on September 30, 2024.
- Over the past year, AXSM quarterly CFF has increased by +$30.41 million (+1520350.00%).
- AXSM quarterly CFF is now -87.64% below its all-time high of $246.08 million, reached on June 30, 2023.
Performance
AXSM Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$43.59 M
-$2.96 M-6.37%
September 30, 2024
Summary
- As of February 7, 2025, AXSM TTM cash flow from financing activities is $43.59 million, with the most recent change of -$2.96 million (-6.37%) on September 30, 2024.
- Over the past year, AXSM TTM CFF has dropped by -$287.42 million (-86.83%).
- AXSM TTM CFF is now -90.84% below its all-time high of $475.66 million, reached on June 30, 2023.
Performance
AXSM TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
AXSM Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +16.3% | +10000.0% | -86.8% |
| 3 y3 years | +680.5% | +6830.7% | +247.9% |
| 5 y5 years | +3198.9% | +5760.6% | -82.7% |
AXSM Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +2874.1% | -87.6% | +2661.5% | -90.8% | +291.7% |
| 5 y | 5-year | at high | +2874.1% | -87.6% | +2661.5% | -90.8% | +291.7% |
| alltime | all time | at high | +8804.7% | -87.6% | +2661.5% | -90.8% | >+9999.0% |
Axsome Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $30.41 M(+111.5%) | $43.59 M(-6.4%) |
| Jun 2024 | - | $14.38 M(-1311.3%) | $46.56 M(-83.3%) |
| Mar 2024 | - | -$1.19 M(>+9900.0%) | $278.26 M(-15.9%) |
| Dec 2023 | $331.01 M(+16.3%) | -$2000.00(-100.0%) | $331.01 M(-0.3%) |
| Sep 2023 | - | $33.37 M(-86.4%) | $332.08 M(-30.2%) |
| Jun 2023 | - | $246.08 M(+377.2%) | $475.66 M(+55.9%) |
| Mar 2023 | - | $51.56 M(+4737.2%) | $305.05 M(+7.2%) |
| Dec 2022 | $284.58 M(+2456.9%) | $1.07 M(-99.4%) | $284.58 M(+0.1%) |
| Sep 2022 | - | $176.95 M(+134.5%) | $284.21 M(+163.9%) |
| Jun 2022 | - | $75.46 M(+142.6%) | $107.70 M(+214.9%) |
| Mar 2022 | - | $31.10 M(+4402.3%) | $34.20 M(+207.3%) |
| Dec 2021 | $11.13 M(-73.8%) | $690.80 K(+57.5%) | $11.13 M(-11.2%) |
| Sep 2021 | - | $438.70 K(-77.7%) | $12.53 M(-68.3%) |
| Jun 2021 | - | $1.97 M(-75.4%) | $39.52 M(-20.7%) |
| Mar 2021 | - | $8.03 M(+284.2%) | $49.81 M(+17.4%) |
| Dec 2020 | $42.41 M(-83.2%) | $2.09 M(-92.4%) | $42.41 M(-81.9%) |
| Sep 2020 | - | $27.43 M(+123.6%) | $234.22 M(+13.0%) |
| Jun 2020 | - | $12.27 M(+1847.5%) | $207.31 M(-3.5%) |
| Mar 2020 | - | $629.80 K(-99.7%) | $214.86 M(-14.9%) |
| Dec 2019 | $252.39 M | $193.89 M(>+9900.0%) | $252.39 M(+276.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | $518.80 K(-97.4%) | $67.04 M(-0.4%) |
| Jun 2019 | - | $19.82 M(-48.0%) | $67.31 M(+37.7%) |
| Mar 2019 | - | $38.16 M(+346.7%) | $48.88 M(+387.2%) |
| Dec 2018 | $10.03 M(-58.0%) | $8.54 M(+981.5%) | $10.03 M(-1.0%) |
| Sep 2018 | - | $789.80 K(-43.4%) | $10.13 M(+7.0%) |
| Jun 2018 | - | $1.40 M(-301.3%) | $9.47 M(+16.2%) |
| Mar 2018 | - | -$693.40 K(-108.0%) | $8.15 M(-65.9%) |
| Dec 2017 | $23.88 M(+139.6%) | $8.64 M(+6550.5%) | $23.88 M(-5.2%) |
| Sep 2017 | - | $129.90 K(+73.7%) | $25.20 M(+0.5%) |
| Jun 2017 | - | $74.80 K(-99.5%) | $25.08 M(+0.3%) |
| Mar 2017 | - | $15.04 M(+51.1%) | $25.01 M(+150.9%) |
| Dec 2016 | $9.97 M(-81.1%) | $9.95 M(>+9900.0%) | $9.97 M(-78.2%) |
| Sep 2016 | - | $14.70 K(>+9900.0%) | $45.69 M(-0.3%) |
| Jun 2016 | - | $0.00(-100.0%) | $45.80 M(-13.4%) |
| Dec 2015 | $52.88 M(+931.5%) | $45.67 M(>+9900.0%) | $52.88 M(+633.7%) |
| Sep 2015 | - | $133.50 K(-98.0%) | $7.21 M(+1.9%) |
| Jun 2015 | - | $6.83 M(+2726.7%) | $7.07 M(+2826.7%) |
| Mar 2015 | - | $241.70 K | $241.70 K |
| Dec 2014 | $5.13 M(+37.9%) | - | - |
| Dec 2013 | $3.72 M | - | - |
FAQ
- What is Axsome Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Axsome Therapeutics?
- What is Axsome Therapeutics annual CFF year-on-year change?
- What is Axsome Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Axsome Therapeutics?
- What is Axsome Therapeutics quarterly CFF year-on-year change?
- What is Axsome Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Axsome Therapeutics?
- What is Axsome Therapeutics TTM CFF year-on-year change?
What is Axsome Therapeutics annual cash flow from financing activities?
The current annual CFF of AXSM is $331.01 M
What is the all time high annual CFF for Axsome Therapeutics?
Axsome Therapeutics all-time high annual cash flow from financing activities is $331.01 M
What is Axsome Therapeutics annual CFF year-on-year change?
Over the past year, AXSM annual cash flow from financing activities has changed by +$46.43 M (+16.32%)
What is Axsome Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of AXSM is $30.41 M
What is the all time high quarterly CFF for Axsome Therapeutics?
Axsome Therapeutics all-time high quarterly cash flow from financing activities is $246.08 M
What is Axsome Therapeutics quarterly CFF year-on-year change?
Over the past year, AXSM quarterly cash flow from financing activities has changed by +$30.41 M (+1520350.00%)
What is Axsome Therapeutics TTM cash flow from financing activities?
The current TTM CFF of AXSM is $43.59 M
What is the all time high TTM CFF for Axsome Therapeutics?
Axsome Therapeutics all-time high TTM cash flow from financing activities is $475.66 M
What is Axsome Therapeutics TTM CFF year-on-year change?
Over the past year, AXSM TTM cash flow from financing activities has changed by -$287.42 M (-86.83%)